Retatrutide has attracted significant attention because early clinical research produced substantial changes in body weight. Understanding those results requires looking at how the trial was designed, who participated, what researchers measured, and what the study could not establish. The pivotal Phase 2 study was a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine. It evaluated retatrutide in 338 adults with obesity or overwe

Retatrutide has become one of the most closely watched investigational compounds in metabolic research. Much of the attention comes from its unusual mechanism: instead of targeting only one hormone receptor, retatrutide activates three — GIP, GLP-1 and glucagon receptors. That makes the question “How is retatrutide different from a GLP-1?” particularly important. The answer is not simply that it is a stronger GLP-1. Retatrutide is a different type of multi-receptor agonist be